ES2137900A1 - Use of formulations based on a water-soluble fraction of Phlebodium decumanum as a nutritional complement in the treatment of the cachectic syndrome in oncological patients. - Google Patents

Use of formulations based on a water-soluble fraction of Phlebodium decumanum as a nutritional complement in the treatment of the cachectic syndrome in oncological patients.

Info

Publication number
ES2137900A1
ES2137900A1 ES009801139A ES9801139A ES2137900A1 ES 2137900 A1 ES2137900 A1 ES 2137900A1 ES 009801139 A ES009801139 A ES 009801139A ES 9801139 A ES9801139 A ES 9801139A ES 2137900 A1 ES2137900 A1 ES 2137900A1
Authority
ES
Spain
Prior art keywords
treatment
soluble fraction
water
formulations
oncological patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES009801139A
Other languages
Spanish (es)
Other versions
ES2137900B1 (en
Inventor
Ferrer Miguel Yesares
Medina Jorge A Mendoza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HELECHOS INTERNACIONAL HONDURA
Helsint SAL
Original Assignee
HELECHOS INTERNACIONAL HONDURA
Helsint SAL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HELECHOS INTERNACIONAL HONDURA, Helsint SAL filed Critical HELECHOS INTERNACIONAL HONDURA
Priority to ES009801139A priority Critical patent/ES2137900B1/en
Priority to PCT/ES1998/000220 priority patent/WO1999006058A1/en
Priority to EP98935039A priority patent/EP1040834A1/en
Publication of ES2137900A1 publication Critical patent/ES2137900A1/en
Application granted granted Critical
Publication of ES2137900B1 publication Critical patent/ES2137900B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Use of formulations based on a water-soluble fraction of Phlebodium decumanum as a nutritional complement in the treatment of the cachectic syndrome in oncological patients. The formulations include EXPLY-37, a purified and standardized water-soluble fraction of fronds of the variety of Phlebodium decumanum cultivated on the Lago Yojoa plantation (Honduras), together with, optionally, Phlebodium decumanum rhizome and the appropriate excipients for the presentation of these formulations in powder, capsule or syrup form. These formulations are suitable for the treatment by the oral route of the cachectic syndrome in oncological patients and as adjuvants in conventional oncological treatments (surgery and/or radiotherapy and chemotherapy) and in the recuperation of oncological patients after undergoing said treatments.
ES009801139A 1997-07-30 1998-06-02 USE OF FORMULATIONS BASED ON A WATER-SOLUBLE FRACTION OF PHLEBODIUM DECUMANUM AS A NUTRITIONAL SUPPLEMENT IN THE TREATMENT OF KAQUECTIC SYNDROME IN ONCOLOGICAL PATIENTS. Expired - Fee Related ES2137900B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES009801139A ES2137900B1 (en) 1998-06-02 1998-06-02 USE OF FORMULATIONS BASED ON A WATER-SOLUBLE FRACTION OF PHLEBODIUM DECUMANUM AS A NUTRITIONAL SUPPLEMENT IN THE TREATMENT OF KAQUECTIC SYNDROME IN ONCOLOGICAL PATIENTS.
PCT/ES1998/000220 WO1999006058A1 (en) 1997-07-30 1998-07-29 Hydrosoluble fractions of phlebodium decumanum and use thereof as nutritional complements in aids and cancer patients
EP98935039A EP1040834A1 (en) 1997-07-30 1998-07-29 HYDROSOLUBLE FRACTIONS OF $i(PHLEBODIUM DECUMANUM) AND USE THEREOF AS NUTRITIONAL COMPLEMENTS IN AIDS AND CANCER PATIENTS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES009801139A ES2137900B1 (en) 1998-06-02 1998-06-02 USE OF FORMULATIONS BASED ON A WATER-SOLUBLE FRACTION OF PHLEBODIUM DECUMANUM AS A NUTRITIONAL SUPPLEMENT IN THE TREATMENT OF KAQUECTIC SYNDROME IN ONCOLOGICAL PATIENTS.

Publications (2)

Publication Number Publication Date
ES2137900A1 true ES2137900A1 (en) 1999-12-16
ES2137900B1 ES2137900B1 (en) 2000-08-16

Family

ID=8303982

Family Applications (1)

Application Number Title Priority Date Filing Date
ES009801139A Expired - Fee Related ES2137900B1 (en) 1997-07-30 1998-06-02 USE OF FORMULATIONS BASED ON A WATER-SOLUBLE FRACTION OF PHLEBODIUM DECUMANUM AS A NUTRITIONAL SUPPLEMENT IN THE TREATMENT OF KAQUECTIC SYNDROME IN ONCOLOGICAL PATIENTS.

Country Status (1)

Country Link
ES (1) ES2137900B1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES471572A1 (en) * 1978-07-07 1979-01-16 Conrad Ltd Anti-psoriatic fern extracts
ES8104315A1 (en) * 1980-04-02 1981-04-16 Conrad Ltd Arthritis treatment with fern extracts
EP0503208A1 (en) * 1991-03-08 1992-09-16 Maracuyama International, S.A. Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns
ES2068163B1 (en) * 1994-05-06 1995-09-01 Esp Farmaceuticas Centrum Sa PROCEDURE FOR OBTAINING A PLANT EXTRACT WITH ACTIVITY IN THE TREATMENT OF COGNITIVE DYSFUNCTIONS AND / OR NEUROINMUNES.
ES2088770A1 (en) * 1995-02-23 1996-09-01 Esp Farmaceuticas Centrum Sa A pharmaceutical composition with activity in the treatment of cognitive and/or neuroimmune dysfunctions.
WO1997023233A1 (en) * 1995-12-21 1997-07-03 Parbold Investments N.V. Biologically active compositions and their use

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES471572A1 (en) * 1978-07-07 1979-01-16 Conrad Ltd Anti-psoriatic fern extracts
ES8104315A1 (en) * 1980-04-02 1981-04-16 Conrad Ltd Arthritis treatment with fern extracts
EP0503208A1 (en) * 1991-03-08 1992-09-16 Maracuyama International, S.A. Procedure for obtaining a natural water-soluble extract from the leaves and/or rhizomes of various immunologically active ferns
ES2068163B1 (en) * 1994-05-06 1995-09-01 Esp Farmaceuticas Centrum Sa PROCEDURE FOR OBTAINING A PLANT EXTRACT WITH ACTIVITY IN THE TREATMENT OF COGNITIVE DYSFUNCTIONS AND / OR NEUROINMUNES.
ES2088770A1 (en) * 1995-02-23 1996-09-01 Esp Farmaceuticas Centrum Sa A pharmaceutical composition with activity in the treatment of cognitive and/or neuroimmune dysfunctions.
WO1997023233A1 (en) * 1995-12-21 1997-07-03 Parbold Investments N.V. Biologically active compositions and their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HORVATH, A. et al. Metabolic effects of Calagualine, an antitumoral saponine of Polypodium leucotomos. NATURE, Londres, Junio 1967. Vol. no 214, paginas 1256-1258. *

Also Published As

Publication number Publication date
ES2137900B1 (en) 2000-08-16

Similar Documents

Publication Publication Date Title
ECSP083351A (en) PHARMACEUTICAL COMPOSITIONS
TR200002299T2 (en) Epothilon compositions.
AP9801392A0 (en) Concentrated antibody preparation.
NO20012774D0 (en) Preparation and method using essential plant oils
WO2004112711A3 (en) Oral extended-release composition
CY1105170T1 (en) ORAL PRESCRIPTION OF LIGHTNING - MELTING DOSAGE
HUP0001382A2 (en) Extended release formulations of erythromycin derivatives
HK1060694A1 (en) Herbal compositions useful as chemopreventive and therapeutic agents.
DK0703786T3 (en) Use of nona- and decapeptides for the manufacture of a medicament for the treatment of AIDS
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
ES2137900A1 (en) Use of formulations based on a water-soluble fraction of Phlebodium decumanum as a nutritional complement in the treatment of the cachectic syndrome in oncological patients.
NO20033699L (en) Stable pharmaceutical formulation comprising torsemide modification II
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
WO2001034174A3 (en) Methods for administration of therapeutic agents on an antiangiogenic schedule
DE58904108D1 (en) DRUG.
ES2124675A1 (en) Formulations based on a water-soluble fraction of Phlebodium decumanum, and use thereof in the treatment of the cachectic syndrome in AIDS patients
AU3478600A (en) Treatment of autoimmune diseases with american ginseng extract
MD2068F1 (en) Method of treatment of the Herpes simplex infection
UA28031C2 (en) Medicinal form of derivatives 5-nitroimidasole, pharmaceutical composition for gastrointestinal tract parasitic and infectious deseases treatment. gastroprotected microgranules of derivatives 5-nitroimidasole, microgranules of derivatives 5-nitroimidasole with a prolonged release of a medicinal agent.
RU2001134578A (en) A method for the treatment of chronic intestinal diseases associated with dysbiosis
UA29645A (en) Natural drug (variants)
GEP20002177B (en) Ointment “Levaskani” for Treatment of Wounds and Burns
UA36542A (en) Denture
DE50211461D1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BULBOPHYLLUM

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19991216

Kind code of ref document: A1

Effective date: 19991216

FD1A Patent lapsed

Effective date: 20070604